Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18614225 | 0.79 | FABP5 (0.45) | FABP5FABP7EPHX2KMT2ACA1 | |
| SCHEMBL18614273 | 0.78 | FABP5 (0.42) | FABP5FABP7EPHX2KMT2ACA1 | |
| SCHEMBL525667 | 0.78 | FABP5 (0.51) | FABP5FABP7EPHX2KMT2ACA1 | |
| SCHEMBL17699252 | 0.77 | FABP5 (0.50) | FABP5FABP7EPHX2KMT2ACA1 | |
| SCHEMBL525363 | 0.76 | FABP5 (0.49) | FABP5FABP7EPHX2KMT2ACA1 | |
| SCHEMBL4600775 | 0.76 | FABP5 (0.42) | FABP5FABP7EPHX2KMT2ACA1 | |
| SCHEMBL29666831 | 0.76 | FABP5 (0.48) | FABP5FABP7EPHX2KMT2A | |
| SCHEMBL524690 | 0.75 | FABP5 (0.48) | FABP5FABP7EPHX2KMT2ACA1 | |
| SCHEMBL7401416 | 0.74 | FABP5 (0.47) | FABP5FABP7EPHX2KMT2ACA1 | |
| SCHEMBL4600771 | 0.74 | FABP5 (0.45) | FABP5FABP7EPHX2KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345789-B2 | Specific inhibitors and active site probes for legumain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-05-24 | — | — | US | claimed |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-10-04 | — | — | US | claimed |
| WO-2011075678-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-06-23 | — | — | WO | claimed |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4482578-B1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025051912-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR INHIBITORS | SANOFI (FR) | 2025-03-13 | — | — | WO | disclosed |
| EP-4482578-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | Corteria Pharmaceuticals (FR) | 2025-01-01 | — | — | EP | disclosed |
| EP-4370532-A2 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Biotech, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117980320-A | Bicyclic peptide inhibitors of interleukin-23 receptor | 詹森生物科技公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023161229-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2023-08-31 | — | — | WO | disclosed |
| EP-4234574-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | Corteria Pharmaceuticals (FR) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023288017-A2 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20180186860-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | U.S. DEPARTMENT OF ENERGY | 2018-07-05 | — | — | US | disclosed |
| WO-2017044899-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| US-9345789-B2 | Specific inhibitors and active site probes for legumain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2011075678-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | ENGASE, LGMN, DNPEP | FABP5 3489/4885FABP7 2640/4885EPHX2 567/4885 |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | GIPR, NPY2R, NPY1R | FABP5 512/4885FABP7 354/4885EPHX2 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.